<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Clin. Diabetes Healthc.</journal-id>
<journal-title>Frontiers in Clinical Diabetes and Healthcare</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Clin. Diabetes Healthc.</abbrev-journal-title>
<issn pub-type="epub">2673-6616</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcdhc.2022.846162</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Clinical Diabetes and Healthcare</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The Psychological Implications of Automated Insulin Delivery Systems in Type 1 Diabetes Care</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Nefs</surname><given-names>Giesje</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/978868"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Medical Psychology, Radboud University Medical Center, Radboud Institute for Health Sciences</institution>, <addr-line>Nijmegen</addr-line>, <country>Netherlands</country></aff>
<aff id="aff2"><sup>2</sup><institution>Diabeter, National Treatment and Research Center for Children, Adolescents and Adults With Type 1 Diabetes</institution>, <addr-line>Rotterdam</addr-line>, <country>Netherlands</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Medical and Clinical Psychology, Center of Research On Psychological Disorders and Somatic Diseases (CoRPS), Tilburg University</institution>, <addr-line>Tilburg</addr-line>, <country>Netherlands</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Alan M. Delamater, University of Miami, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Michael Harris, Oregon Health and Science University, United States; Catherine Davis, Augusta University, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Giesje Nefs, <email xlink:href="mailto:Giesje.Nefs@radboudumc.nl">Giesje.Nefs@radboudumc.nl</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Diabetes Self-Management, a section of the journal Frontiers in Clinical Diabetes and Healthcare</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>03</day>
<month>05</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>3</volume>
<elocation-id>846162</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>12</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>03</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Nefs</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Nefs</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Automated insulin delivery (AID) systems have brought important glycemic benefits to type 1 diabetes management. The present paper provides an overview of their psychological implications. Trials and real-world observational studies report improvements in diabetes-specific quality of life, with qualitative work describing reduced management burden, increased flexibility and improved relationships. Not all experiences are positive, however, evidenced by dropping algorithm use soon after device initiation. Apart from finance and logistics, reasons for discontinuation include technology frustrations, wear-related issues and unmet glycemic and work load expectations. New challenges include distrust in proper AID functioning, overreliance and deskilling, compensatory behaviors to override or trick the system and optimize time in range, and concerns related to wearing multiple devices on the body. Research efforts may focus on incorporating a diversity perspective, updating existing person-reported outcome measures according to new technology developments, addressing implicit or explicit health professional bias in technology access, examining the merits of incorporating stress reactivity in the AID algorithm, and developing concrete approaches for psychological counseling and support related to technology use. An open dialogue with health professionals and peers about expectations, preferences and needs may foster the collaboration between the person with diabetes and the AID system.</p>
</abstract>
<kwd-group>
<kwd>diabetes</kwd>
<kwd>technology</kwd>
<kwd>closed-loop</kwd>
<kwd>self-management</kwd>
<kwd>behavior</kwd>
<kwd>psychology</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="59"/>
<page-count count="6"/>
<word-count count="2719"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Recent years have witnessed rapid advancements in technological devices assisting in insulin delivery and glucose monitoring in type 1 diabetes (T1D) care, with the goal of improving glucose levels to more closely resemble those in people without diabetes. Integration of insulin pump and sensor technologies has progressed from low-glucose and predictive low-glucose suspension (insulin cessation when sensor glucose crosses or is predicted to cross the low threshold level) to automated insulin delivery (AID) systems (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B3">3</xref>).</p>
<p>Also called artificial pancreas or hybrid closed-loop, these systems focus on algorithm-driven partially automated insulin delivery based on sensor readings. Initial hybrid systems combining automated basal insulin delivery with manual meal and residual correction boluses have swiftly been advanced with autocorrection boluses, meal detection, as well as more personalized treatment options (e.g. multiple target set points) and new algorithm enhancements are underway (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B3">3</xref>).</p>
<p>There are several commercial AID systems available in routine diabetes care, with multiple others being developed [for an overview, please refer to (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B3">3</xref>)]. Dual-hormone closed loop systems are also finding their way to the market, adding other hormones to more closely imitate physiological glucose regulation (<xref ref-type="bibr" rid="B4">4</xref>). Unregulated open-source or Do-It-Yourself systems have been co-created by online communities and provide open-access algorithms for building one&#x2019;s own AID system, allowing considerable user customization (<xref ref-type="bibr" rid="B5">5</xref>). Randomized controlled trials and real-world clinical studies examining the safety and efficacy of AID systems generally find a reduction in HbA<sub>1c</sub> and hypoglycemia, as well as an increase of time in range (70-180 mg/dL or 3.9-10.0 mmol/L) to an average of 65-75%, even higher during nighttime and in select populations (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B6">6</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>).</p>
<p>The objective of this paper is to provide an overview of the psychological implications of AID systems.</p>
</sec>
<sec id="s2">
<title>Psychological Benefits</title>
<p>A growing number of trials and real-world observational studies focusing on AID systems have included person-reported outcome (PRO) measures to evaluate quality of life changes alongside glycemic benefits. Most of these report improvements in diabetes-specific distress or at least suggest technology advancements do not necessarily lead to added diabetes burden (<xref ref-type="bibr" rid="B10">10</xref>&#x2013;<xref ref-type="bibr" rid="B15">15</xref>), although previous glycemic burdens might be exchanged for new technology burdens (<xref ref-type="bibr" rid="B15">15</xref>). While not found consistently, AID systems may also have positive effects on subjective and objective sleep of people with T1D (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B16">16</xref>&#x2013;<xref ref-type="bibr" rid="B21">21</xref>). Comparing two AID system generations in a randomized crossover trial among adolescents and adults, the advanced system improved satisfaction with the emotional and behavioral burden of glucose monitoring when compared with its predecessor; diabetes distress and hypoglycemia confidence were similar (<xref ref-type="bibr" rid="B22">22</xref>). Qualitative studies further detail the quality of life benefits of AID systems, describing a reduction of self-management burden and worries, increased flexibility and spontaneity, as well as improvements in relationships (<xref ref-type="bibr" rid="B23">23</xref>&#x2013;<xref ref-type="bibr" rid="B25">25</xref>).</p>
</sec>
<sec id="s3">
<title>Discontinuation</title>
<p>Despite potential glycemic and quality of life benefits, not all experiences are positive. While higher use of the algorithm has been associated with more optimal glycemic outcomes (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B26">26</xref>), consistent use of the closed-loop feature may drop soon, even to an average of 50% by six months in some &#x2013; particularly younger - samples (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B27">27</xref>). Furthermore, up to one-third of users of a first generation AID system stopped using the algorithm altogether by 3-6 months (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B28">28</xref>), although these numbers might be more hopeful for later technologies (<xref ref-type="bibr" rid="B7">7</xref>). In a demographically diverse adult population, 31% of AID users even never initiated the closed-loop feature (<xref ref-type="bibr" rid="B29">29</xref>). Reasons for discontinuation center on reimbursement and supply difficulties, technology frustrations, wear-related issues, unexpectedly high work load, fears and preferences, life intrusions, discouragement (e.g. when glycemic benefit expectations are not met), and other life stressors (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>). Preliminary quantitative studies focusing on a first-generation system suggest that higher baseline HbA<sub>1c</sub> is predictive of lower use of the algorithm, potentially due to increased perceived self-care burden to keep the system going (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B30">30</xref>), although those with high HbA<sub>1c</sub> also stand more to gain (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>). Early behavioral device data such as algorithm use and exits in the first 1-3 months may help to identify difficulties early on (<xref ref-type="bibr" rid="B30">30</xref>). Furthermore, from the sensor literature, it is known that individual perceptions of device benefits and burdens are key in continued device use (<xref ref-type="bibr" rid="B33">33</xref>). While benefits and burdens are relatable to most people, individuals may weigh the advantages and disadvantages of the system differently and this personal trade-off also deserves clinical attention (<xref ref-type="bibr" rid="B24">24</xref>).</p>
<p>In a mixed-method observational study, 5% of 874 people using or initiating a Do-It-Yourself closed-loop system self-identified as discontinuers in the year after the baseline assessment (<xref ref-type="bibr" rid="B34">34</xref>). Based on survey results, discontinuation was associated with older age and somewhat lower trust in the system, but not with other demographic, clinical or psychological factors (<xref ref-type="bibr" rid="B34">34</xref>). The most commonly stated reasons for discontinuation related to wanting to try different technologies and unmet benefit expectations (<xref ref-type="bibr" rid="B34">34</xref>). Qualitative themes described the mental burden associated with uptake/use, difficulties with adjusting settings, fear of disapproval by health professionals, technical or logistic barriers, and individual concerns (<xref ref-type="bibr" rid="B34">34</xref>).</p>
</sec>
<sec id="s4">
<title>New Challenges</title>
<sec id="s4_1">
<title>Trust</title>
<p>In order to optimally benefit from AID, users have to release some control over diabetes management to the algorithm. This means developing an <italic>appropriate</italic> level over trust in the system, as technology to date is far from perfect and user vigilance is still needed (<xref ref-type="bibr" rid="B35">35</xref>). There often is an initial probation period of several weeks, in which users evaluate device accuracy by closely monitoring system actions and glucose levels, sometimes backed by a temporary increase of fingerpricks (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B35">35</xref>). Trust may increase when glycemic results correspond more closely with personal beliefs about effect and safety (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B35">35</xref>). At the same time, the algorithm&#x2019;s learning process requires the user to refrain from micromanaging and let the system occasionally pick up falling or rising glucose levels at a slower and more dosed pace (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). Limited possibilities for communicating day-to-day contextual variations may lead to additional frustrations (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B35">35</xref>).</p>
<p>Even in experienced users, trust is highly context-specific, where people tend to have least confidence in the system&#x2019;s proper handling of exercise and meal situations (<xref ref-type="bibr" rid="B35">35</xref>). Development of trust is also related to personal factors, with those having self-managed diabetes for many years reporting more skepticism (<xref ref-type="bibr" rid="B35">35</xref>). For some people confidence in the system is built only after a sense of understanding the algorithm (<xref ref-type="bibr" rid="B23">23</xref>), although for present commercial systems some of its workings may still feel like a black box and trust remains conditional on glucose levels in the here and now (<xref ref-type="bibr" rid="B24">24</xref>). Most people eventually find a collaborative partnership with the AID system to optimize glucose management and quality of life (<xref ref-type="bibr" rid="B23">23</xref>).</p>
</sec>
<sec id="s4_2">
<title>Dependence and Deskilling</title>
<p>Many users of an AID system appreciate its ability to achieve glycemic outcomes beyond their own capabilities and to function as a back-up when needed, e.g. in case of unplanned physical activity, carbohydrate miscalculations or missed boluses (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B36">36</xref>). For some, this is mixed with significant anticipatory anxiety about having to manage glucose on their own again (<xref ref-type="bibr" rid="B35">35</xref>), for example in case of system break-down. Firm reliance on the algorithm to address glucose fluctuations may also lead to forgetting to carry out key tasks, deskilling (e.g. in terms of carbohydrate counting) and less healthy eating (more snacking, increased portions, more high-fat energy-dense foods) (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B36">36</xref>&#x2013;<xref ref-type="bibr" rid="B39">39</xref>).</p>
</sec>
<sec id="s4_3">
<title>Compensatory Behaviors</title>
<p>Behaviors that contribute to optimal glycemic outcomes in open loop may bring new challenges in the context of closed loop, requiring significant cognitive and emotional efforts to give over enough control to an &#x2013; as yet &#x2013; imperfect system in order for it to improve performance (<xref ref-type="bibr" rid="B24">24</xref>). Frustrations with and distrust in the proper functioning of the AID system may lead to several user actions to retain personal control. Efforts to override or trick the system into delivering extra insulin may be more common than realized, as many people are hesitant to tell health care providers and peers about these actions (<xref ref-type="bibr" rid="B24">24</xref>). Compensatory behaviors include temporarily stepping back to open loop or employing workarounds such as entering fake carbohydrates (also called phantomboluses) (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B35">35</xref>). Furthermore, as the algorithm works best with few external challenges, some people actively limit physical activity or intake of carbohydrates to further increase their time in range (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B40">40</xref>). Given known technology shortcomings, having an open dialogue about the goals and consequences of these compensatory behaviors is the most constructive way for optimizing human-device interactions (<xref ref-type="bibr" rid="B24">24</xref>).</p>
</sec>
<sec id="s4_4">
<title>Bodily Concerns</title>
<p>Bodily concerns are important reasons for diabetes technology non-adoption or discontinuation in general (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>). These range from practical frustrations as well as pain and discomfort to more aesthetic and experiential aspects, such as increased self-consciousness, unwanted social visibility, and altered body or self-image (<xref ref-type="bibr" rid="B43">43</xref>&#x2013;<xref ref-type="bibr" rid="B45">45</xref>).</p>
<p>Current AID systems may echo (<xref ref-type="bibr" rid="B36">36</xref>) as well as complicate these issues by requiring people to wear two or sometimes even three devices on the body. This may particularly become apparent in the context of relationship intimacy, where people simultaneously manage prevention of device dislodgements and not hurting a partner as well as their relationship itself (<xref ref-type="bibr" rid="B46">46</xref>).</p>
</sec>
</sec>
<sec id="s5">
<title>Developments and Future Outlook</title>
<sec id="s5_1">
<title>Diversity Perspective</title>
<p>An important limitation of the studies reviewed in this paper is that they have mostly included majority populations without significant health disparities. It remains to be determined whether their challenges are generalizable to underrepresented and underserved populations. Specific challenges may go beyond barriers to technology use related to costs, availability and prescription bias. For example, in a small study among 32 adults with T1D treated at an academic urban safety-net hospital who were prescribed a first generation AID system, black and Hispanic people were overrepresented in the group who never initiated auto-mode despite similar insurance and educational level to the rest of the sample (<xref ref-type="bibr" rid="B29">29</xref>). Given potential glycemic and quality of life benefits, future research is encouraged to identify strategies for increasing uptake and continued use of AID systems in underserved populations (<xref ref-type="bibr" rid="B29">29</xref>).</p>
<p>A broader age perspective is also needed. While some device struggles appear to be similar across the lifespan, others may differ in expression and emphasis for different age groups (<xref ref-type="bibr" rid="B47">47</xref>). For example, adolescents and young adults may struggle with AID systems due to interference with regular developmental tasks related to body image, identity, independence and peer relations (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B42">42</xref>) while older adults may face additional management challenges including a higher risk of severe hypoglycemia and long-term complications as well as sleep disruption and problems related to cognition, dexterity, and vision (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B48">48</xref>).</p>
</sec>
<sec id="s5_2">
<title>Measurement of Psychological Impact</title>
<p>The impact of AID systems may go well beyond glycemic parameters and meaningfully influence quality of life. Regular person-reported outcome (PRO) assessment may be of value, e.g. to track psychological problems interfering with optimal AID functioning such as fear of hypoglycemia and related behaviors including taking many extra carbohydrates at night. However, in a preliminary study, common measures of diabetes distress and worries about hypoglycemia did not predict algorithm use after one year; therefore, these tools might not tap sufficiently into the psychology of technology use (<xref ref-type="bibr" rid="B30">30</xref>). Instruments are available to measure specific perceptions and experiences related to AID therapy, including the INSPIRE questionnaires and adaptations of the Technology Acceptance Scale (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B49">49</xref>). In the upcoming years, these will need to be updated according to new psychological issues arising with further technology advancements.</p>
</sec>
<sec id="s5_3">
<title>Psychological Factors as Selection Criteria</title>
<p>The assessment of characteristics in light of identifying predictors of device success is not straightforward. Behavioral and medical factors such as &#x2265;4 blood glucose checks per day and higher sensor use prior to algorithm initialization have been associated with more frequent use of the algorithm and higher improvements in glycemic outcomes (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B50">50</xref>), but there is a limited number of studies and results are not always consistent, e.g. with respect to HbA<sub>1c</sub> level. Furthermore, personal definitions of benefit may differ (e.g. in terms of glucometrics, acute complications, continued system use, person-reported outcomes) and getting the support from health professionals in transitioning to AID technology may itself stimulate increased diabetes self-care engagement (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B51">51</xref>). Selection procedures may even be counterproductive for the working relation between the person with T1D and their health professionals in terms of inappropriate subjective gatekeeping to technology access (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B52">52</xref>). In the REPOSE trial, staff described applying their own perceptions of personal and psychological suitability (e.g. in terms of higher education, technological comprehension) in recommending people for insulin pump therapy in regular care, which proved to be incorrect in multiple instances with random therapy allocation (<xref ref-type="bibr" rid="B51">51</xref>). Similar assumptions were found and challenged in the CLOuD trial focusing on AID technology (<xref ref-type="bibr" rid="B38">38</xref>). In the context of AID therapy, people with suboptimal self-management behaviors and glycemic outcomes at system start described relatively easy adaptation and great benefits, while relinquishing control to the algorithm was especially challenging for people with lower initial HbA<sub>1c</sub> and higher personal standards for diabetes management (<xref ref-type="bibr" rid="B24">24</xref>). In this respect, measurement of psychological factors &#x2013; similar to social and health factors such as socioeconomic status, social support, visual or dexterity impairments, psychopathology, cognition - should only serve as input for stimulating an open discussion about AID initiation/continuation and mapping the support needed for an individual to access optimal benefits of advanced technologies.</p>
</sec>
<sec id="s5_4">
<title>Integration of Psychological Information in AID Algorithms</title>
<p>Integration of other information to algorithms may further increase AID performance (<xref ref-type="bibr" rid="B1">1</xref>). One factor to consider is the effect of psychological stress on insulin sensitivity and glucose levels. While there is large inter- and intra-individual variability in stress-reactivity, daily stressors may increase glucose variability (<xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B54">54</xref>). Therefore, more research is warranted to examine the potential predictive contribution of stress and other situational/behavioral factors to AID algorithms (<xref ref-type="bibr" rid="B54">54</xref>). To capture the complexity of the stress &#x2013; glucose link in the context of AID therapy, these studies preferably incorporate ecological momentary assessments over longer time periods (<xref ref-type="bibr" rid="B54">54</xref>).</p>
</sec>
<sec id="s5_5">
<title>Psychological Counseling and Support</title>
<p>&#x201c;One size fits all&#x201d; does not apply to T1D care (<xref ref-type="bibr" rid="B55">55</xref>), with some people making well-informed and well-considered personal decisions against AID adoption and continued use. However, many people currently unnecessarily do not fully benefit from AID therapy. Apart from changes at the policy level (e.g. broader reimbursement), health professionals as well as peers have an important role to play in this respect. This starts with increased awareness of their own technology attitudes and experiences (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B51">51</xref>). Opportunities for support further include guiding appropriate expectations, offering structured education programs and providing tailored strategies for managing device hassles as personal preferences may differ (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B57">57</xref>). More studies are needed to assist the development of more concrete conversational and interventional tools in this respect. Interesting developments include behavioral telehealth interventions such as ONBOARD (focusing on sensor use, including the themes of discomfort, data overload, trust and unwanted social attention) and virtual reality exposure to technology barriers relating to body image, hassles of use, worries about losing skills, and unwanted social attention (<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B59">59</xref>).</p>
</sec>
</sec>
<sec id="s6">
<title>Conclusion</title>
<p>AID systems offer the potential of significant glycemic and quality of life benefits to people with T1D. As long as devices remain visibly worn on the body and still require at least some human effort, a better understanding of person-technology interactions remains key. Psychology offers several tools for measuring the quality of life impact of AID systems and may bring important insights for addressing cognitive, emotional or behavioral barriers towards optimal use. Central to all efforts is an ongoing dialogue, with efforts to maximize benefits and minimize burdens of AID therapy and with sensitivity to the personal trade-off between both.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author Contributions</title>
<p>The author confirms being the sole contributor of this work and has approved it for publication.</p>
</sec>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of Interest</title>
<p>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boughton</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Hovorka</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>New Closed-Loop Insulin Systems</article-title>. <source>Diabetologia</source> (<year>2021</year>) <volume>64</volume>(<issue>5</issue>):<page-range>1007&#x2013;15</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00125-021-05391-w</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leelarathna</surname> <given-names>L</given-names>
</name>
<name>
<surname>Choudhary</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wilmot</surname> <given-names>EG</given-names>
</name>
<name>
<surname>Lumb</surname> <given-names>A</given-names>
</name>
<name>
<surname>Street</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kar</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Hybrid Closed-Loop Therapy: Where are We in 2021</article-title>? <source>Diabetes Obes Metab</source> (<year>2021</year>) <volume>23</volume>(<issue>3</issue>):<page-range>655&#x2013;60</page-range>. doi: <pub-id pub-id-type="doi">10.1111/dom.14273</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pauley</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Berget</surname> <given-names>C</given-names>
</name>
<name>
<surname>Messer</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Forlenza</surname> <given-names>GP</given-names>
</name>
</person-group>. <article-title>Barriers to Uptake of Insulin Technologies and Novel Solutions</article-title>. <source>Med Devices (Auckl)</source> (<year>2021</year>) <volume>14</volume>:<page-range>339&#x2013;54</page-range>. doi: <pub-id pub-id-type="doi">10.2147/MDER.S312858</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Infante</surname> <given-names>M</given-names>
</name>
<name>
<surname>Baidal</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Rickels</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Fabbri</surname> <given-names>A</given-names>
</name>
<name>
<surname>Skyler</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Alejandro</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Dual-Hormone Artificial Pancreas for Management of Type 1 Diabetes: Recent Progress and Future Directions</article-title>. <source>Artif Organs</source> (<year>2021</year>) <volume>45</volume>(<issue>9</issue>):<page-range>968&#x2013;86</page-range>. doi: <pub-id pub-id-type="doi">10.1111/aor.14023</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braune</surname> <given-names>K</given-names>
</name>
<name>
<surname>Lal</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Petruzelkova</surname> <given-names>L</given-names>
</name>
<name>
<surname>Scheiner</surname> <given-names>G</given-names>
</name>
<name>
<surname>Winterdijk</surname> <given-names>P</given-names>
</name>
<name>
<surname>Schmidt</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Open-Source Automated Insulin Delivery: International Consensus Statement and Practical Guidance for Health-Care Professionals</article-title>. <source>Lancet Diabetes Endocrinol</source> (<year>2022</year>) <volume>10</volume>(<issue>1</issue>):<fpage>58</fpage>&#x2013;<lpage>74</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2213-8587(21)00267-9</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Da Silva</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lepore</surname> <given-names>G</given-names>
</name>
<name>
<surname>Battelino</surname> <given-names>T</given-names>
</name>
<name>
<surname>Arrieta</surname> <given-names>A</given-names>
</name>
<name>
<surname>Castaneda</surname> <given-names>J</given-names>
</name>
<name>
<surname>Grosman</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Real-World Performance of the MiniMed 780g System: First Report of Outcomes From 4'120 Users</article-title>. <source>Diabetes Technol Ther</source> (<year>2022</year>) <volume>24</volume>(<issue>2</issue>):<page-range>113&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2021.0203</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breton</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Kovatchev</surname> <given-names>BP</given-names>
</name>
</person-group>. <article-title>One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology</article-title>. <source>Diabetes Technol Ther</source> (<year>2021</year>) <volume>23</volume>(<issue>9</issue>):<page-range>601&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2021.0097</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kesavadev</surname> <given-names>J</given-names>
</name>
<name>
<surname>Srinivasan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Saboo</surname> <given-names>B</given-names>
</name>
<name>
<surname>Krishna</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Krishnan</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>The Do-It-Yourself Artificial Pancreas: A Comprehensive Review</article-title>. <source>Diabetes Ther</source> (<year>2020</year>) <volume>11</volume>(<issue>6</issue>):<page-range>1217&#x2013;35</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s13300-020-00823-z</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stone</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Agrawal</surname> <given-names>P</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cordero</surname> <given-names>TL</given-names>
</name>
<etal/>
</person-group>. <article-title>Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670g System Commercial Launch</article-title>. <source>Diabetes Technol Ther</source> (<year>2018</year>) <volume>20</volume>(<issue>10</issue>):<page-range>689&#x2013;92</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2018.0202</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinsker</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Muller</surname> <given-names>L</given-names>
</name>
<name>
<surname>Constantin</surname> <given-names>A</given-names>
</name>
<name>
<surname>Leas</surname> <given-names>S</given-names>
</name>
<name>
<surname>Manning</surname> <given-names>M</given-names>
</name>
<name>
<surname>McElwee Malloy</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Real-World Patient-Reported Outcomes and Glycemic Results With Initiation of Control-IQ Technology</article-title>. <source>Diabetes Technol Ther</source> (<year>2021</year>) <volume>23</volume>(<issue>2</issue>):<page-range>120&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2020.0388</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kudva</surname> <given-names>YC</given-names>
</name>
<name>
<surname>Laffel</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Raghinaru</surname> <given-names>D</given-names>
</name>
<name>
<surname>Pinsker</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Ekhlaspour</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial</article-title>. <source>Diabetes Technol Ther</source> (<year>2021</year>) <volume>23</volume>(<issue>10</issue>):<page-range>673&#x2013;83</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2021.0089</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cobry</surname> <given-names>EC</given-names>
</name>
<name>
<surname>Kanapka</surname> <given-names>LG</given-names>
</name>
<name>
<surname>Cengiz</surname> <given-names>E</given-names>
</name>
<name>
<surname>Carria</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ekhlaspour</surname> <given-names>L</given-names>
</name>
<name>
<surname>Buckingham</surname> <given-names>BA</given-names>
</name>
<etal/>
</person-group>. <article-title>Health-Related Quality of Life and Treatment Satisfaction in Parents and Children With Type 1 Diabetes Using Closed-Loop Control</article-title>. <source>Diabetes Technol Ther</source> (<year>2021</year>) <volume>23</volume>(<issue>6</issue>):<page-range>401&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2020.0532</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname> <given-names>RN</given-names>
</name>
<name>
<surname>Tanenbaum</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Hanes</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Ambrosino</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Ly</surname> <given-names>TT</given-names>
</name>
<name>
<surname>Maahs</surname> <given-names>DM</given-names>
</name>
<etal/>
</person-group>. <article-title>Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management</article-title>. <source>Diabetes Technol Ther</source> (<year>2018</year>) <volume>20</volume>(<issue>10</issue>):<page-range>648&#x2013;53</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2018.0174</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beato-Vibora</surname> <given-names>PI</given-names>
</name>
<name>
<surname>Gallego-Gamero</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ambrojo-Lopez</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gil-Poch</surname> <given-names>E</given-names>
</name>
<name>
<surname>Martin-Romo</surname> <given-names>I</given-names>
</name>
<name>
<surname>Arroyo-Diez</surname> <given-names>FJ</given-names>
</name>
</person-group>. <article-title>Amelioration of User Experiences and Glycaemic Outcomes With an Advanced Hybrid Closed Loop System in a Real-World Clinical Setting</article-title>. <source>Diabetes Res Clin Pract</source> (<year>2021</year>) <volume>178</volume>:<fpage>108986</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.diabres.2021.108986</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berget</surname> <given-names>C</given-names>
</name>
<name>
<surname>Messer</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Vigers</surname> <given-names>T</given-names>
</name>
<name>
<surname>Frohnert</surname> <given-names>BI</given-names>
</name>
<name>
<surname>Pyle</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wadwa</surname> <given-names>RP</given-names>
</name>
<etal/>
</person-group>. <article-title>Six Months of Hybrid Closed Loop in the Real-World: An Evaluation of Children and Young Adults Using the 670G System</article-title>. <source>Pediatr Diabetes</source> (<year>2020</year>) <volume>21</volume>(<issue>2</issue>):<page-range>310&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1111/pedi.12962</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malone</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Peleckis</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Grunin</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>G</given-names>
</name>
<name>
<surname>Jang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Weimer</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Characterizing Glycemic Control and Sleep in Adults With Long-Standing Type 1 Diabetes and Hypoglycemia Unawareness Initiating Hybrid Closed Loop Insulin Delivery</article-title>. <source>J Diabetes Res</source> (<year>2021</year>) <volume>2021:6611064</volume>. doi: <pub-id pub-id-type="doi">10.1155/2021/6611064</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wheeler</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>Collyns</surname> <given-names>OJ</given-names>
</name>
<name>
<surname>Meier</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Betts</surname> <given-names>ZL</given-names>
</name>
<name>
<surname>Frampton</surname> <given-names>C</given-names>
</name>
<name>
<surname>Frewen</surname> <given-names>CM</given-names>
</name>
<etal/>
</person-group>. <article-title>Improved Technology Satisfaction and Sleep Quality With Medtronic MiniMed(R) Advanced Hybrid Closed-Loop Delivery Compared to Predictive Low Glucose Suspend in People With Type 1 Diabetes in a Randomized Crossover Trial</article-title>. <source>Acta Diabetol</source> (<year>2020</year>) <volume>69</volume> (<supplement>Supplement_1</supplement>): <fpage>979&#x2013;P</fpage>. doi: <pub-id pub-id-type="doi">10.2337/db20-979-P</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bisio</surname> <given-names>A</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>SA</given-names>
</name>
<name>
<surname>McFadden</surname> <given-names>R</given-names>
</name>
<name>
<surname>Pajewski</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>PL</given-names>
</name>
<name>
<surname>DeBoer</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Sleep and Diabetes-Specific Psycho-Behavioral Outcomes of a New Automated Insulin Delivery System in Young Children With Type 1 Diabetes and Their Parents</article-title>. <source>Pediatr Diabetes</source> (<year>2021</year>) <volume>22</volume>(<issue>3</issue>):<fpage>495</fpage>&#x2013;<lpage>502</lpage>. doi: <pub-id pub-id-type="doi">10.1111/pedi.13164</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bisio</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gonder-Frederick</surname> <given-names>L</given-names>
</name>
<name>
<surname>McFadden</surname> <given-names>R</given-names>
</name>
<name>
<surname>Chernavvsky</surname> <given-names>D</given-names>
</name>
<name>
<surname>Voelmle</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pajewski</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>The Impact of a Recently Approved Automated Insulin Delivery System on Glycemic, Sleep, and Psychosocial Outcomes in Older Adults With Type 1 Diabetes: A Pilot Study</article-title>. <source>J Diabetes Sci Technol</source> (<year>2021</year>) <fpage>1932296820986879</fpage>. doi: <pub-id pub-id-type="doi">10.1177/1932296820986879</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cobry</surname> <given-names>EC</given-names>
</name>
<name>
<surname>Hamburger</surname> <given-names>E</given-names>
</name>
<name>
<surname>Jaser</surname> <given-names>SS</given-names>
</name>
</person-group>. <article-title>Impact of the Hybrid Closed-Loop System on Sleep and Quality of Life in Youth With Type 1 Diabetes and Their Parents</article-title>. <source>Diabetes Technol Ther</source> (<year>2020</year>) <volume>22</volume>(<issue>11</issue>):<fpage>794</fpage>&#x2013;<lpage>800</lpage>. doi: <pub-id pub-id-type="doi">10.1089/dia.2020.0057</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmer</surname> <given-names>W</given-names>
</name>
<name>
<surname>Greeley</surname> <given-names>SAW</given-names>
</name>
<name>
<surname>Letourneau-Freiberg</surname> <given-names>LR</given-names>
</name>
<name>
<surname>Naylor</surname> <given-names>RN</given-names>
</name>
</person-group>. <article-title>Using a Do-It-Yourself Artificial Pancreas: Perspectives From Patients and Diabetes Providers</article-title>. <source>J Diabetes Sci Technol</source> (<year>2020</year>) <volume>14</volume>(<issue>5</issue>):<page-range>860&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1177/1932296820942258</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hood</surname> <given-names>KK</given-names>
</name>
<name>
<surname>Laffel</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Danne</surname> <given-names>T</given-names>
</name>
<name>
<surname>Nimri</surname> <given-names>R</given-names>
</name>
<name>
<surname>Weinzimer</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Sibayan</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives</article-title>. <source>Diabetes Technol Ther</source> (<year>2021</year>) <volume>23</volume>(<issue>12</issue>):<page-range>857&#x2013;61</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2021.0153</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lawton</surname> <given-names>J</given-names>
</name>
<name>
<surname>Blackburn</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rankin</surname> <given-names>D</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Campbell</surname> <given-names>FM</given-names>
</name>
<name>
<surname>Leelarathna</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Participants' Experiences of, and Views About, Daytime Use of a Day-And-Night Hybrid Closed-Loop System in Real Life Settings: Longitudinal Qualitative Study</article-title>. <source>Diabetes Technol Ther</source> (<year>2019</year>) <volume>21</volume>(<issue>3</issue>):<page-range>119&#x2013;27</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2018.0306</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>LR</given-names>
</name>
<name>
<surname>Malcolm</surname> <given-names>J</given-names>
</name>
<name>
<surname>Arnaout</surname> <given-names>A</given-names>
</name>
<name>
<surname>Humphrey-Murto</surname> <given-names>S</given-names>
</name>
<name>
<surname>LaDonna</surname> <given-names>KA</given-names>
</name>
</person-group>. <article-title>Real-World Patient Experience of Long-Term Hybrid Closed-Loop Insulin Pump Use</article-title>. <source>Can. J Diabetes</source> (<year>2021</year>) <volume>45</volume>(<issue>8</issue>):<fpage>750</fpage>&#x2013;<lpage>6.e3</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcjd.2021.02.006</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rankin</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kimbell</surname> <given-names>B</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Besser</surname> <given-names>REJ</given-names>
</name>
<name>
<surname>Boughton</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Campbell</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Adolescents' Experiences of Using a Smartphone Application Hosting a Closed-Loop Algorithm to Manage Type 1 Diabetes in Everyday Life: Qualitative Study</article-title>. <source>J Diabetes Sci Technol</source> (<year>2021</year>) <volume>15</volume>(<issue>5</issue>):<page-range>1042&#x2013;51</page-range>. doi: <pub-id pub-id-type="doi">10.1177/1932296821994201</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lal</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Basina</surname> <given-names>M</given-names>
</name>
<name>
<surname>Maahs</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Hood</surname> <given-names>K</given-names>
</name>
<name>
<surname>Buckingham</surname> <given-names>B</given-names>
</name>
<name>
<surname>Wilson</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System</article-title>. <source>Diabetes Care</source> (<year>2019</year>) <volume>42</volume>(<issue>12</issue>):<page-range>2190&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.2337/dc19-0855</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berget</surname> <given-names>C</given-names>
</name>
<name>
<surname>Akturk</surname> <given-names>HK</given-names>
</name>
<name>
<surname>Messer</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Vigers</surname> <given-names>T</given-names>
</name>
<name>
<surname>Pyle</surname> <given-names>L</given-names>
</name>
<name>
<surname>Snell-Bergeon</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Real-World Performance of Hybrid Closed Loop in Youth, Young Adults, Adults and Older Adults With Type 1 Diabetes: Identifying a Clinical Target for Hybrid Closed-Loop Use</article-title>. <source>Diabetes Obes Metab</source> (<year>2021</year>) <volume>23</volume>(<issue>9</issue>):<page-range>2048&#x2013;57</page-range>. doi: <pub-id pub-id-type="doi">10.1111/dom.14441</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messer</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Berget</surname> <given-names>C</given-names>
</name>
<name>
<surname>Vigers</surname> <given-names>T</given-names>
</name>
<name>
<surname>Pyle</surname> <given-names>L</given-names>
</name>
<name>
<surname>Geno</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wadwa</surname> <given-names>RP</given-names>
</name>
<etal/>
</person-group>. <article-title>Real World Hybrid Closed-Loop Discontinuation: Predictors and Perceptions of Youth Discontinuing the 670G System in the First 6 Months</article-title>. <source>Pediatr Diabetes</source> (<year>2020</year>) <volume>21</volume>(<issue>2</issue>):<page-range>319&#x2013;27</page-range>. doi: <pub-id pub-id-type="doi">10.1111/pedi.12971</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ju</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Piarulli</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bielick</surname> <given-names>L</given-names>
</name>
<name>
<surname>Marschall</surname> <given-names>S</given-names>
</name>
<name>
<surname>Brouillard</surname> <given-names>E</given-names>
</name>
<name>
<surname>Steenkamp</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Advanced Diabetes Technology Remains Underutilized in Underserved Populations: Early Hybrid Closed-Loop System Experience at an Academic Safety Net Hospital</article-title>. <source>Diabetes Technol Ther</source> (<year>2022</year>) <volume>24</volume>(<issue>2</issue>):<page-range>143&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2021.0334</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forlenza</surname> <given-names>GP</given-names>
</name>
<name>
<surname>Vigers</surname> <given-names>T</given-names>
</name>
<name>
<surname>Berget</surname> <given-names>C</given-names>
</name>
<name>
<surname>Messer</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Lal</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Basina</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Predicting Success With a First-Generation Hybrid Closed-Loop Artificial Pancreas System Among Children, Adolescents, and Young Adults With Type 1 Diabetes: A Model Development and Validation Study</article-title>. <source>Diabetes Technol Ther</source> (<year>2022</year>) <volume>24</volume>(<issue>3</issue>):<page-range>157&#x2013;66</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2021.0326</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akturk</surname> <given-names>HK</given-names>
</name>
<name>
<surname>Giordano</surname> <given-names>D</given-names>
</name>
<name>
<surname>Champakanath</surname> <given-names>A</given-names>
</name>
<name>
<surname>Brackett</surname> <given-names>S</given-names>
</name>
<name>
<surname>Garg</surname> <given-names>S</given-names>
</name>
<name>
<surname>Snell-Bergeon</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Long-Term Real-Life Glycaemic Outcomes With a Hybrid Closed-Loop System Compared With Sensor-Augmented Pump Therapy in Patients With Type 1 Diabetes</article-title>. <source>Diabetes Obes Metab</source> (<year>2020</year>) <volume>22</volume>(<issue>4</issue>):<page-range>583&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1111/dom.13933</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forlenza</surname> <given-names>GP</given-names>
</name>
<name>
<surname>Breton</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Kovatchev</surname> <given-names>BP</given-names>
</name>
</person-group>. <article-title>Candidate Selection for Hybrid Closed Loop Systems</article-title>. <source>Diabetes Technol Ther</source> (<year>2021</year>) <volume>23</volume>(<issue>11</issue>):<page-range>760&#x2013;2</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2021.0217</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messer</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Cook</surname> <given-names>PF</given-names>
</name>
<name>
<surname>Lowe</surname> <given-names>NK</given-names>
</name>
<name>
<surname>Hood</surname> <given-names>KK</given-names>
</name>
<name>
<surname>Driscoll</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Hernandez</surname> <given-names>TL</given-names>
</name>
</person-group>. <article-title>Predicting Optimal Use of Continuous Glucose Monitors in Adolescents With Type 1 Diabetes: It's About Benefit and Burden</article-title>. <source>J Pediatr Nurs</source> (<year>2022</year>) <volume>62</volume>:<page-range>23&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.pedn.2021.11.016</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname> <given-names>J</given-names>
</name>
<name>
<surname>Suttiratana</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lal</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Lum</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lanning</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Dunlap</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Discontinued Use of the Loop Insulin Dosing System: A Mixed-Methods Investigation</article-title>. <source>Diabetes Technol Ther</source> (<year>2022</year>) <volume>24</volume>(<issue>4</issue>):<page-range>241&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2021.0362</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanenbaum</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Iturralde</surname> <given-names>E</given-names>
</name>
<name>
<surname>Hanes</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Suttiratana</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Ambrosino</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Ly</surname> <given-names>TT</given-names>
</name>
<etal/>
</person-group>. <article-title>Trust in Hybrid Closed Loop Among People With Diabetes: Perspectives of Experienced System Users</article-title>. <source>J Health Psychol</source> (<year>2020</year>) <volume>25</volume>(<issue>4</issue>):<page-range>429&#x2013;38</page-range>. doi: <pub-id pub-id-type="doi">10.1177/1359105317718615</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rankin</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kimbell</surname> <given-names>B</given-names>
</name>
<name>
<surname>Hovorka</surname> <given-names>R</given-names>
</name>
<name>
<surname>Lawton</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Adolescents' and Their Parents' Experiences of Using a Closed-Loop System to Manage Type 1 Diabetes in Everyday Life: Qualitative Study</article-title>. <source>Chronic Illn</source> (<year>2021</year>) <fpage>1742395320985924</fpage>. doi: <pub-id pub-id-type="doi">10.1177/1742395320985924</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lawton</surname> <given-names>J</given-names>
</name>
<name>
<surname>Blackburn</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rankin</surname> <given-names>D</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Campbell</surname> <given-names>F</given-names>
</name>
<name>
<surname>Leelarathna</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>The Impact of Using a Closed-Loop System on Food Choices and Eating Practices Among People With Type 1 Diabetes: A Qualitative Study Involving Adults, Teenagers and Parents</article-title>. <source>Diabetes Med</source> (<year>2019</year>) <volume>36</volume>(<issue>6</issue>):<page-range>753&#x2013;60</page-range>. doi: <pub-id pub-id-type="doi">10.1111/dme.13887</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lawton</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kimbell</surname> <given-names>B</given-names>
</name>
<name>
<surname>Rankin</surname> <given-names>D</given-names>
</name>
<name>
<surname>Ashcroft</surname> <given-names>NL</given-names>
</name>
<name>
<surname>Varghese</surname> <given-names>L</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>Health Professionals' Views About Who Would Benefit From Using a Closed-Loop System: A Qualitative Study</article-title>. <source>Diabetes Med</source> (<year>2020</year>) <volume>37</volume>(<issue>6</issue>):<page-range>1030&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1111/dme.14252</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kahkoska</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Mayer-Davis</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Hood</surname> <given-names>KK</given-names>
</name>
<name>
<surname>Maahs</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Burger</surname> <given-names>KS</given-names>
</name>
</person-group>. <article-title>Behavioural Implications of Traditional Treatment and Closed-Loop Automated Insulin Delivery Systems in Type 1 Diabetes: Applying a Cognitive Restraint Theory Framework</article-title>. <source>Diabetes Med</source> (<year>2017</year>) <volume>34</volume>(<issue>11</issue>):<page-range>1500&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1111/dme.13407</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lehmann</surname> <given-names>V</given-names>
</name>
<name>
<surname>Zueger</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zeder</surname> <given-names>A</given-names>
</name>
<name>
<surname>Scott</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bally</surname> <given-names>L</given-names>
</name>
<name>
<surname>Laimer</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Lower Daily Carbohydrate Intake Is Associated With Improved Glycemic Control in Adults With Type 1 Diabetes Using a Hybrid Closed-Loop System</article-title>. <source>Diabetes Care</source> (<year>2020</year>) <volume>43</volume>(<issue>12</issue>):<page-range>3102&#x2013;5</page-range>. doi: <pub-id pub-id-type="doi">10.2337/dc20-1560</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanenbaum</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Hanes</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Naranjo</surname> <given-names>D</given-names>
</name>
<name>
<surname>Bensen</surname> <given-names>R</given-names>
</name>
<name>
<surname>Hood</surname> <given-names>KK</given-names>
</name>
</person-group>. <article-title>Diabetes Device Use in Adults With Type 1 Diabetes: Barriers to Uptake and Potential Intervention Targets</article-title>. <source>Diabetes Care</source> (<year>2017</year>) <volume>40</volume>(<issue>2</issue>):<page-range>181&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.2337/dc16-1536</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messer</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Tanenbaum</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Cook</surname> <given-names>PF</given-names>
</name>
<name>
<surname>Wong</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Hanes</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Driscoll</surname> <given-names>KA</given-names>
</name>
<etal/>
</person-group>. <article-title>Cost, Hassle, and On-Body Experience: Barriers to Diabetes Device Use in Adolescents and Potential Intervention Targets</article-title>. <source>Diabetes Technol Ther</source> (<year>2020</year>) <volume>22</volume>(<issue>10</issue>):<page-range>760&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2019.0509</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reidy</surname> <given-names>C</given-names>
</name>
<name>
<surname>Bracher</surname> <given-names>M</given-names>
</name>
<name>
<surname>Foster</surname> <given-names>C</given-names>
</name>
<name>
<surname>Vassilev</surname> <given-names>I</given-names>
</name>
<name>
<surname>Rogers</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>The Process of Incorporating Insulin Pumps Into the Everyday Lives of People With Type 1 Diabetes: A Critical Interpretive Synthesis</article-title>. <source>Health Expect</source> (<year>2018</year>) <volume>21</volume>(<issue>4</issue>):<page-range>714&#x2013;29</page-range>. doi: <pub-id pub-id-type="doi">10.1111/hex.12666</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayes</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fearson</surname> <given-names>S</given-names>
</name>
<name>
<surname>Keller</surname> <given-names>C</given-names>
</name>
<name>
<surname>Cartmale</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lewis-Hayes</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>A Hermeneutic Phenomenological Study of Why Adults With Type 1 Diabetes Choose to Discontinue CSII</article-title>. <source>Eur Diabetes Nursing</source> (<year>2011</year>) <volume>8</volume>(<issue>1</issue>):<page-range>12&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1002/edn.167</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messer</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>R</given-names>
</name>
<name>
<surname>Driscoll</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Jones</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Best Friend or Spy: A Qualitative Meta-Synthesis on the Impact of Continuous Glucose Monitoring on Life With Type 1 Diabetes</article-title>. <source>Diabetes Med</source> (<year>2018</year>) <volume>35</volume>(<issue>4</issue>):<page-range>409&#x2013;18</page-range>. doi: <pub-id pub-id-type="doi">10.1111/dme.13568</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garza</surname> <given-names>KP</given-names>
</name>
<name>
<surname>Weil</surname> <given-names>LEG</given-names>
</name>
<name>
<surname>Anderson</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Naranjo</surname> <given-names>D</given-names>
</name>
<name>
<surname>Barnard-Kelly</surname> <given-names>KD</given-names>
</name>
<name>
<surname>Laffel</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>You, Me, and Diabetes: Intimacy and Technology Among Adults With T1D and Their Partners</article-title>. <source>Fam Syst Health</source> (<year>2020</year>) <volume>38</volume>(<issue>4</issue>):<page-range>418&#x2013;27</page-range>. doi: <pub-id pub-id-type="doi">10.1037/fsh0000485</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naranjo</surname> <given-names>D</given-names>
</name>
<name>
<surname>Suttiratana</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Iturralde</surname> <given-names>E</given-names>
</name>
<name>
<surname>Barnard</surname> <given-names>KD</given-names>
</name>
<name>
<surname>Weissberg-Benchell</surname> <given-names>J</given-names>
</name>
<name>
<surname>Laffel</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>What End Users and Stakeholders Want From Automated Insulin Delivery Systems</article-title>. <source>Diabetes Care</source> (<year>2017</year>) <volume>40</volume>(<issue>11</issue>):<page-range>1453&#x2013;61</page-range>. doi: <pub-id pub-id-type="doi">10.2337/dc17-0400</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhaliwal</surname> <given-names>R</given-names>
</name>
<name>
<surname>Weinstock</surname> <given-names>RS</given-names>
</name>
</person-group>. <article-title>Management of Type 1 Diabetes in Older Adults</article-title>. <source>Diabetes Spectr</source> (<year>2014</year>) <volume>27</volume>(<issue>1</issue>):<fpage>9</fpage>&#x2013;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.2337/diaspect.27.1.9</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weissberg-Benchell</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shapiro</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Hood</surname> <given-names>K</given-names>
</name>
<name>
<surname>Laffel</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Naranjo</surname> <given-names>D</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Assessing Patient-Reported Outcomes for Automated Insulin Delivery Systems: The Psychometric Properties of the INSPIRE Measures</article-title>. <source>Diabetes Med</source> (<year>2019</year>) <volume>36</volume>(<issue>5</issue>):<page-range>644&#x2013;52</page-range>. doi: <pub-id pub-id-type="doi">10.1111/dme.13930</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messer</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Berget</surname> <given-names>C</given-names>
</name>
<name>
<surname>Pyle</surname> <given-names>L</given-names>
</name>
<name>
<surname>Vigers</surname> <given-names>T</given-names>
</name>
<name>
<surname>Cobry</surname> <given-names>E</given-names>
</name>
<name>
<surname>Driscoll</surname> <given-names>KA</given-names>
</name>
<etal/>
</person-group>. <article-title>Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth With Type 1 Diabetes</article-title>. <source>Diabetes Technol Ther</source> (<year>2021</year>) <volume>23</volume>(<issue>12</issue>):<page-range>837&#x2013;43</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2021.0165</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lawton</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kirkham</surname> <given-names>J</given-names>
</name>
<name>
<surname>Rankin</surname> <given-names>D</given-names>
</name>
<name>
<surname>White</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Elliott</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jaap</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Who Gains Clinical Benefit From Using Insulin Pump Therapy? A Qualitative Study of the Perceptions and Views of Health Professionals Involved in the Relative Effectiveness of Pumps Over MDI and Structured Education (REPOSE) Trial</article-title>. <source>Diabetes Med</source> (<year>2016</year>) <volume>33</volume>(<issue>2</issue>):<page-range>243&#x2013;51</page-range>. doi: <pub-id pub-id-type="doi">10.1111/dme.12879</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kubiak</surname> <given-names>T</given-names>
</name>
<name>
<surname>Priesterroth</surname> <given-names>L</given-names>
</name>
<name>
<surname>Barnard-Kelly</surname> <given-names>KD</given-names>
</name>
</person-group>. <article-title>Psychosocial Aspects of Diabetes Technology</article-title>. <source>Diabetes Med</source> (<year>2020</year>) <volume>37</volume>(<issue>3</issue>):<page-range>448&#x2013;54</page-range>. doi: <pub-id pub-id-type="doi">10.1111/dme.14234</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riazi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Pickup</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bradley</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Daily Stress and Glycaemic Control in Type 1 Diabetes: Individual Differences in Magnitude, Direction, and Timing of Stress-Reactivity</article-title>. <source>Diabetes Res Clin Pract</source> (<year>2004</year>) <volume>66</volume>(<issue>3</issue>):<page-range>237&#x2013;44</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.diabres.2004.04.001</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonder-Frederick</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Grabman</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Kovatchev</surname> <given-names>B</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Patek</surname> <given-names>S</given-names>
</name>
<name>
<surname>Basu</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Is Psychological Stress a Factor for Incorporation Into Future Closed-Loop Systems</article-title>? <source>J Diabetes Sci Technol</source> (<year>2016</year>) <volume>10</volume>(<issue>3</issue>):<page-range>640&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1177/1932296816635199</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonder-Frederick</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Shepard</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Grabman</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Ritterband</surname> <given-names>LM</given-names>
</name>
</person-group>. <article-title>Psychology, Technology, and Diabetes Management</article-title>. <source>Am Psychol</source> (<year>2016</year>) <volume>71</volume>(<issue>7</issue>):<page-range>577&#x2013;89</page-range>. doi: <pub-id pub-id-type="doi">10.1037/a0040383</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messer</surname> <given-names>LH</given-names>
</name>
</person-group>. <article-title>Why Expectations Will Determine the Future of Artificial Pancreas</article-title>. <source>Diabetes Technol Ther</source> (<year>2018</year>) <volume>20</volume>(<issue>S2</issue>):<page-range>S265&#x2013;S8</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2018.0116</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perkins</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Cardinez</surname> <given-names>N</given-names>
</name>
<name>
<surname>Opsteen</surname> <given-names>CF</given-names>
</name>
</person-group>. <article-title>Talking Points for Helping Your Type 1 Diabetes Patient Decide About Hybrid Closed Loop</article-title>. <source>Can J Diabetes</source> (<year>2020</year>) <volume>44</volume>(<issue>4</issue>):<page-range>356&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jcjd.2019.10.004</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanenbaum</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Ngo</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hanes</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Basina</surname> <given-names>M</given-names>
</name>
<name>
<surname>Buckingham</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Hessler</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>ONBOARD: A Feasibility Study of a Telehealth-Based Continuous Glucose Monitoring Adoption Intervention for Adults With Type 1 Diabetes</article-title>. <source>Diabetes Technol Ther</source> (<year>2021</year>) <volume>23</volume>(<issue>12</issue>):<page-range>818&#x2013;27</page-range>. doi: <pub-id pub-id-type="doi">10.1089/dia.2021.0198</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lanning</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wasser</surname> <given-names>D</given-names>
</name>
<name>
<surname>Riddle</surname> <given-names>S</given-names>
</name>
<name>
<surname>Agustin</surname> <given-names>B</given-names>
</name>
<name>
<surname>Hood</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Exposure to Closed Loop Barriers Using Virtual Reality</article-title>. <source>J Diabetes Sci Technol</source> (<year>2020</year>) <volume>14</volume>(<issue>5</issue>):<page-range>837&#x2013;43</page-range>. doi: <pub-id pub-id-type="doi">10.1177/1932296820902771</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>